Trials / Recruiting
RecruitingNCT06237777
A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients
An Open, Dose-escalation Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients in China
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Wang Min · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106 intravitreal injection in diabetic macular edema (DME) patients.
Detailed description
This is an open, dose-escalation clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106 intravitreal injection in diabetic macular edema (DME) patients in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | SKG0106 intravitreal injection dose level 1, 2 or 3 | SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product. |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
- First posted
- 2024-02-01
- Last updated
- 2024-04-30
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06237777. Inclusion in this directory is not an endorsement.